Novo Nordisk A/S (NYSE:NVO) Shares Purchased by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC increased its position in Novo Nordisk A/S (NYSE:NVO) by 9.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,798 shares of the company’s stock after buying an additional 2,038 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,156,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of NVO. Gabelli Funds LLC lifted its holdings in Novo Nordisk A/S by 35.7% in the 2nd quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock valued at $6,703,000 after acquiring an additional 12,363 shares during the last quarter. Dalton Investments Inc. acquired a new stake in Novo Nordisk A/S during the second quarter valued at approximately $1,299,000. Itau Unibanco Holding S.A. bought a new stake in Novo Nordisk A/S during the second quarter worth approximately $3,592,000. Fidelis Capital Partners LLC grew its position in Novo Nordisk A/S by 6.2% in the second quarter. Fidelis Capital Partners LLC now owns 9,813 shares of the company’s stock worth $1,401,000 after buying an additional 573 shares during the last quarter. Finally, Epoch Investment Partners Inc. increased its holdings in shares of Novo Nordisk A/S by 4.5% in the second quarter. Epoch Investment Partners Inc. now owns 14,132 shares of the company’s stock valued at $2,017,000 after buying an additional 614 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NVO shares. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Argus raised their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday, September 16th. Finally, The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Price Performance

NVO opened at $127.51 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. Novo Nordisk A/S has a 1 year low of $86.96 and a 1 year high of $148.15. The stock has a fifty day moving average price of $133.13 and a 200 day moving average price of $133.26. The stock has a market cap of $572.21 billion, a price-to-earnings ratio of 43.97, a PEG ratio of 1.48 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Analysts forecast that Novo Nordisk A/S will post 3.11 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is 24.83%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.